Evidence map›Paper›PMID 39682626›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Somatostatin Receptor Imaging in the Diagnosis and Management of Parathyroid Neuroendocrine Neoplasia.

Uliana Tsoy, Karina Pogosian, Daria Ryzhkova, Olga Yudina, Ksenia Yakovenko, Pavel Ryazanov, Irina Matsueva, Polina Sokolnikova, Maksim Salov, Tatiana Karonova and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Uliana TsoyAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Karina PogosianAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Daria RyzhkovaAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Olga YudinaAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Ksenia YakovenkoAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Pavel RyazanovAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Irina MatsuevaAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Polina SokolnikovaAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Maksim SalovAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Tatiana KaronovaAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.
Elena GrinevaAlmazov National Medical Research Centre, 2 Akkuratova Street, Saint Petersburg 197341, Russia.ORCID 0000-0003-0042-7680

Funding

This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation [Agreement No. 075-15-2022-301]. [Agreement No. 075-15-2022-301]
6 · The paper itself

Abstract

backgroundParathyroid tumors are classified as parathyroid neuroendocrine neoplasia (NEN) by the IARC-WHO classification. These tumors can occur with NENs from other sites, which often require total-body [68Ga]-DOTA-peptides PET/CT. This study aimed to assess the utility of [68Ga]-DOTA-peptide PET/CT in imaging parathyroid NENs and to evaluate the underlying mechanisms.

methodsFifty patients with primary hyperparathyroidism (PHPT) and parathyroid NENs histologically confirmed as parathyroid adenomas (PAs) were included. PET/CT with [68Ga]-DOTA-peptide was performed in 16 patients with localized PAs, including 10 with MEN1 syndrome. Somatostatin receptor types 2 and 5 (SST2 and SST5) staining was performed on PAs from 48 patients. Somatostatin analogs (SSA) were prescribed in four patients with MEN 1 syndrome and 1 with persistent acromegaly, all with PAs and PHPT. The therapy effects on calcium and parathyroid hormone (iPTH) were evaluated.

results[68Ga]-DOTA-peptide PET/CT detected 20 PAs with high radiopharmaceutical uptake. SST2 expression was negative on PA cell membranes in all cases and positive on endothelium in 39 (81%) PAs. Membrane SST5 expression was positive in 25 (52%) PAs and endothelial was positive in 40 (83%). Serum calcium levels decreased in patients on SSA therapy, while iPTH did not.

conclusionsPET/CT with [68Ga]-DOTA-peptides can detect parathyroid NENs. The incidental detection of high [68Ga]-DOTA-peptide uptake in the parathyroid region during whole-body PET/CT may prompt biochemical evaluation for PHPT. We suggest that endothelial SST expression mediates high radiopharmaceutical uptake by PAs and that SSA treatment can reduce hypercalcemia in PHPT patients.

Indexed as

parathyroid adenomaparathyroid neuroendocrine neoplasmsPET/CT with 68Ga-DOTA-peptidessomatostatin receptors type 2somatostatin receptors type 5

Identifiers

PMID39682626
PMCPMC11640021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.